EUCTR2015-004816-39-NL进行中（未招募）1 期
A Phase 1/2a Study of BMS-986178 Administered Alone or in Combination with Nivolumab and/or Ipilimumab in subjects with Advanced Solid Tumors.
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 166
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects must be refractory to or intolerant of established therapy known to provide clinical benefit for their condition, i.e., subjects must not be candidates for regimens known to provide clinical benefit
- •ECOG (Eastern Cooperative Oncology Group) 0-1
- •Men and women 18 years old or older
- •At least one measurable lesion at baseline by CT (computed tomography) or MRI (magnetic resonance imaging) as per RECIST (Response Evaluation Criteria In Solid Tumors) v1.1
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 247
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 357
排除标准
- •Known central nervous system metastases or central nervous system as the only source of disease
- •Concomitant malignancies
- •Active known or suspected autoimmune disease
- •Uncontrolled or significant cardiovascular disease
- •Major surgery less than 4 weeks before the start of the study
研究者
相似试验
进行中（未招募）
1 期
Study of BMS-986178 Monotherapy or in Combination With Nivolumaband/or Ipilimumab in Subjects With Advanced Solid Tumors.Advanced Solid TumorsMedDRA version: 21.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 100000004864EUCTR2015-004816-39-ITBRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATIO166
尚未招募
不适用
A Phase 1/2a Study of BMS-986178 Administered Alone or in Combination with Nivolumab and/or Ipilimumab in Subjects with Advanced Solid TumorsDuring the Dose Escalation phase the following tumor histologies permitted except primary CNS tumorsNL-OMON47099Bristol-Myers Squibb20
进行中（未招募）
1 期
Study of BMS-986178 Monotherapy or in Combination With Nivolumab or Ipilimumab in Subjects With Advanced Solid TumorsAdvanced Solid TumorsMedDRA version: 19.0 Level: LLT Classification code 10065252 Term: Solid tumor System Organ Class: 100000004864EUCTR2015-004816-39-ESBristol-Myers Squibb International Corporation245
进行中（未招募）
1 期
Study of BMS-986179 Administered alone and in Combination with Nivolumab (BMS-936558) in Subjects with Advanced Solid TumorsSolid tumorsMedDRA version: 21.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 100000004864EUCTR2016-000603-91-ITBRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATIO235
进行中（未招募）
1 期
Study of BMS-986179 Administered alone and in Combination with Nivolumab (BMS- 936558) in Subjects with Advanced Solid TumorsSolid tumorsMedDRA version: 20.0 Level: LLT Classification code 10065252 Term: Solid tumor System Organ Class: 100000004864EUCTR2016-000603-91-DEBristol-Myers Squibb International Corporation246